Jeito Capital

Jeito Capital is a prominent global investment company headquartered in Paris, France, dedicated to advancing medical innovation. The firm primarily focuses on late-stage biotech and biopharma companies that are developing breakthrough therapeutic solutions. Their investment philosophy centers on identifying and supporting promising medical advancements from clinical development through to market access, aiming to address significant unmet medical needs. Jeito Capital positions itself as a crucial partner for companies navigating the complex journey from scientific discovery to commercialization, providing not only capital but also strategic guidance and operational support.

The firm's investment strategy is characterized by its commitment to substantial, long-term partnerships. Jeito Capital seeks to bridge the funding gap often encountered by innovative medical companies as they transition from venture-backed stages to the public markets or commercialization. Their first fund, Jeito I, successfully closed at €534 million in 2020, demonstrating significant investor confidence in their specialized approach. Building on this success, Jeito II closed at €520 million in 2023, further solidifying their capacity to deploy significant capital into the life sciences sector. These substantial fund sizes enable Jeito to make meaningful investments that can truly accelerate drug development and market entry.

Typically, Jeito Capital's initial investments range from approximately €10 million to €60 million per company, with the potential for follow-on investments that can bring their total commitment up to €100 million over the lifetime of an investment. This substantial check size reflects their focus on later-stage companies that require considerable capital to complete clinical trials, secure regulatory approvals, and prepare for commercial launch. The firm's global reach, combined with its deep industry expertise, allows it to identify and support high-potential companies across Europe and the United States, fostering a portfolio of diverse and impactful medical innovations.